- Home
- DAVA vs RNA Comparison
DAVA vs RNA Comparison
Compare DAVA & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DAVA | RNA |
|---|---|---|
| Founded | 2000 | 2012 |
| Country | United Kingdom | United States |
| Employees | N/A | 391 |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 220.4M | 199.7M |
| IPO Year | 2015 | 2025 |
Fundamental Metrics
Financial Performance| Metric | DAVA | RNA |
|---|---|---|
| Price | $4.16 | $12.92 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 20 |
| Target Price | $13.50 | ★ $69.26 |
| AVG Volume (30 Days) | 216.5K | ★ 322.1K |
| Earning Date | 05-19-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $88.12 |
| Revenue Next Year | $4.07 | $18.11 |
| P/E Ratio | $20.02 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.98 | $11.95 |
| 52 Week High | $20.80 | $73.06 |
Technical Indicators
Market Signals| Indicator | DAVA | RNA |
|---|---|---|
| Relative Strength Index (RSI) | 40.04 | 31.88 |
| Support Level | N/A | $12.85 |
| Resistance Level | $7.04 | $14.80 |
| Average True Range (ATR) | 0.22 | 0.65 |
| MACD | -0.03 | 0.66 |
| Stochastic Oscillator | 17.43 | 17.24 |
Price Performance
Historical ComparisonAbout DAVA Endava plc (each representing one)
Endava is a next-generation IT services company that primarily assists clients with their digital transformation efforts by creating customized software for them. The company was founded in 2006 in the UK, and it continues to generate the majority of revenue in the UK and Europe. Endava's client base is concentrated in the payments and financial services, technology, media, and telecom industries.
About RNA Avidity Biosciences Inc.
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.